2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Nombre del producto No. CAS Pureza Estructura química
  • HY-114080
    Patamostat 114568-26-2 98.13%
    Patamostat (E-3123) is a potent protease inhibitor. Patamostat potently inhibits trypsin, plasmin and thrombin with IC50s of 39 nM, 950 nM and 1.9 μM, respectively. Patamostat may possess suppressing effects on pathogenesis and development of acute pancreatitis.
    Patamostat
  • HY-114227
    Hexidium iodide 211566-66-4 98.88%
    Hexidium iodide, a fluorescent nucleic binding acid stain (excitation/emission ~ 518/600 nm), permeants to mammalian cells and selectively stains almost all gram-positive bacteria. Hexidium iodide can bind to the DNA of all bacteria after permeabilization by EDTA.
    Hexidium iodide
  • HY-114628
    MS012 2089617-83-2 98.9%
    MS012 is a selective GLP inhibitor (IC50=7 nM). MS012 can be used in research of GLP dysregulation, including cancer, inflammatory diseases, and neuroregenerative disorders.
    MS012
  • HY-114727
    PDE7-IN-4 18741-24-7 98.55%
    PDE7-IN-4 is a phosphodiesterase 7 (PDE7) inhibitor with activity that increases intracellular cyclic adenosine monophosphate (cAMP) levels. PDE7-IN-4 shows potential inhibitory effects in neurotransmission and anti-inflammatory applications. PDE7-IN-4 exerts its biological activity by acting on the cAMP/cAMP response element binding protein (CREB) pathway. The development of PDE7-IN-4 aims to improve its pharmacokinetic characteristics to more effectively target neurodegenerative diseases and other inflammation-related diseases.
    PDE7-IN-4
  • HY-115566
    S1PL-IN-1 1538574-95-6 99.9%
    S1PL-IN-31 (compound ) is an oral active sphingosine-1-phosphate (S1P) lyase inhibitor with the IC50 of 210 nM. S1PL-IN-31 is Smoothened receptor antagonist with the IC50 of 440 nM. S1PL-IN-31 can be used for study of experimental autoimmune encephalomyelitis.
    S1PL-IN-1
  • HY-116188
    HX1 1520083-61-7 99.86%
    HX1 is a potent reversible myeloperoxidase (MPO) inhibitor with an IC50 value of 50 nM. HX1 is bound within the active site cavity above the heme and blocks the substrate channel. HX1 is promising for research of inflammatory diseases.
    HX1
  • HY-116227
    (2S,3R)-LP99 1808948-28-8 99.4%
    (2S,3R)-LP99 is a potent and selective BRD7 and BRD9 inhibitor with an KD of 99 nM for BRD9. (2S,3R)-LP99 inhibits the association of BRD7 and BRD9 to acetylated histones in vitro and in cells. (2S,3R)-LP99 demonstrates that BRD7/9 plays a role in regulating pro-inflammatory cytokine secretion.
    (2S,3R)-LP99
  • HY-116449
    2-Benzoylthiophene 135-00-2 ≥98.0%
    2-Benzoylthiophene is an inhibitor of human hematopoietic prostaglandin D2 synthase (H-PGDS) with an IC50 value of 11.4 μM. 2-Benzoylthiophene can be used in the research of inflammatory diseases.
    2-Benzoylthiophene
  • HY-116691
    Hydrocortisone aceponate 74050-20-7 99.43%
    Hydrocortisone aceponate (Hydrocortisone 17-propionate 21-acetate) is a diester-based topical glucocorticoid. Hydrocortisone aceponate alleviates symptoms such as erythema, dryness/desquamation, pruritus, epidermal exfoliation, and exudation/crusting. Hydrocortisone aceponate causes extremely few adverse reactions. Hydrocortisone aceponate is applicable to various dermatological disease studies.
    Hydrocortisone aceponate
  • HY-116953
    Lipoxin B4 98049-69-5 99.20%
    Lipoxin B4 (LXB4) is a structurally distinct product of arachidonic acid metabolism. Lipoxin B4 reduces leukocyte infiltration and mucus secretion in the nasal mucosa and decreases mast cell and eosinophil degranulation in the upper airway. Lipoxin B4 decreases airway inflammation, mucus metaplasia and hyper- responsiveness in the lower airway. Lipoxin B4 shows mucosal protective actions and has the potential for the research of allergic inflammation in the upper and lower airways.
    Lipoxin B4
  • HY-117082
    UTL-5g 646530-37-2 99.92%
    UTL-5g (GBL-5g), an anti-inflammatory TNF-α inhibitor, has chemoprotective and liver radioprotective effects. UTL-5g lowers hepatotoxicity, nephrotoxicity, and myelotoxicity induced by Cisplatin through TNF-α inhibition among other factors.
    UTL-5g
  • HY-117702
    RB 101 135949-60-9 98%
    RB 101 is a blood-brain barrier-crossing prodrug as well as aminopeptidase N and neutral endopeptidase-24.11 inhibitor. RB 101 blocks enkephalin breakdown, elevates extracellular enkephalin levels and activate δ-opioid receptor and dopamine D1 receptor. RB 101 can be used for the research of pain, depressive syndromes, and diabetic neuropathy.
    RB 101
  • HY-117721
    IHVR-11029 1383152-30-4 99.86%
    IHVR-11029 is a small molecule inhibitor of ER α-glucosidases, with an EC50 of 0.09 μM.
    IHVR-11029
  • HY-117977
    FCPR03 1917347-65-9 99.82%
    FCPR03 is a potent and selective phosphodiesterase 4 (PDE4) inhibitor with IC50 values of 60 nM, 31 nM and 47 nM for PDE4 catalytic domain, PDE4B1 and PDE4D7, respectively. FCPR03 displays at least 2100-fold selectivity over other PDEs (PDE1-3 and PDE5-11). FCPR03 has anti-inflammatory, neuroprotective and antidepressant-like effects.
    FCPR03
  • HY-118110
    MLS000545091 322666-76-2 99.92%
    MLS000545091 is a potent and selective lipoxygenase-2 (LOX-2) inhibitor with an IC50 value of 2.6 μM for h15-LOX-2.
    MLS000545091
  • HY-118167
    Monoethylglycinexylidide 7728-40-7 99.69%
    Monoethylglycinexylidide is a metabolite of Lidocain (HY-B0185) via oxidative N-deethylation of Lignocaine by liver cytochrome P-450 enzymes in the liver[1].
    Monoethylglycinexylidide
  • HY-118561
    Bermoprofen 78499-27-1 99.91%
    Bermoprofen (AD-1590) is an orally active non-steroidal anti-inflammatory agent. Bermoprofen has potent antipyretic activities with a short biological half-life. Bermoprofen is a potent antagonist of LPS-induced fever in rabbits.
    Bermoprofen
  • HY-118584
    Ro 12-7310 65316-65-6 98%
    Ro 12-7310 is a synthetic retinoid, and can inhibit arachidonic acid release.
    Ro 12-7310
  • HY-119101
    AZD-5672 780750-65-4
    AZD-5672 is an orally active, potent, and selective CCR5 antagonist (IC50=0.32 nM). AZD-5672 shows moderate activity against the hERG ion channel (binding IC50=7.3 μM). AZD5672 is a substrate of human P-gp, and inhibits P-gp-mediated digoxin transport (IC50=32 μM). AZD-5672 can be used for the research of rheumatoid arthritis.
    AZD-5672
  • HY-119172
    NSC-60339 70-09-7
    NSC-60339, an efflux pump inhibitor and a substrate of AcrAB-TolC, is a polybasic terephthalic acid derivative studied as a potential cancer chemotherapeutic agent.
    NSC-60339
Cat. No. Nombre del producto / Synonyms Application Reactivity